NCT Number: NCT02261090
Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers
Study to compare the oral bioavailability of seven prototype slow-release formulations to immediate-release tablets
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–50 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All participants in the study should be healthy males
- Participants should be ranging from 21 to 50 years of age
- Body mass index (BMI) within 18.5 to 29.9 kg/m2
- In accordance with Good Clinical Practice and the local legislation all volunteers will have given their written informed consent prior to admission to the study
Exclusion criteria
- Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
- Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
- Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial)
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Inability to refrain from smoking on in-house trial days
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation (≥ 100 mL within four weeks prior to administration or during the trial)
- Any laboratory value outside the clinically accepted reference range
- Excessive physical activities within the last week before the trial or during the trial
- Hypersensitivity to pramipexole, or other dopamine agonists
- Supine blood pressure at screening of systolic < 110 mmHg and diastolic < 60 mmHg
- A haemoglobin value at screening of less than 13.5 g/dl (usual lower limit of normal for males: 12.6 g/mL)
- Subjects involved in passenger transport or operation of dangerous machines
Treatment and study plan
Formulation C: Pramipexole Slow release tablet
DrugFormulation D: Pramipexole Slow release tablet
DrugFormulation E: Pramipexole Slow release tablet
DrugFormulation F: Pramipexole Slow release tablet
DrugFormulation G: Pramipexole Slow release tablet
DrugFormulation H: Pramipexole Slow release tablet
DrugPramipexole immediate release (IR) tablets
DrugPrimary outcomes
-
Plasma total exposure (AUCτ,ss)
Time frame: up to 168 hours after each drug administration
-
Urine total exposure (Aeτ,ss)
Time frame: up to 168 hours after each drug administration
-
Plasma maximum exposure (Cmax,ss)
Time frame: up to 168 hours after each drug administration
-
Plasma minimum exposure (Cmin,ss)
Time frame: up to 168 hours after each drug administration
-
Plasma average concentration (Cavg)
Time frame: up to 168 hours after each drug administration
-
Plasma peak to trough fluctuation (PTF)
Time frame: up to 168 hours after each drug administration
Secondary outcomes
-
AUC0-6,11 for the immediate release (IR) formulation
Time frame: day 7 of visit 2
-
Cmax for the IR formulation
Time frame: up to 168 hours after drug administration in visit 2
-
Cmin for the IR formulation
Time frame: up to 168 hours after drug administration in visit 2
-
tmax for the IR formulation
Time frame: up to 168 hours after drug administration in visit 2
-
Urinary excretion (Ae) for the IR formulation
Time frame: up to 168 hours after drug administration in visit 2
-
tmax,4 for the SR formulation
Time frame: up to 96 hours after drug administration in visit 3-5, 7 and 9
-
t1/2,4 for the SR formulation
Time frame: up to 96 hours after drug administration in visit 9
-
Urinary excretion (Ae) for the SR formulation
Time frame: up to 168 hours after drug administration
-
Number of subjects with adverse events
Time frame: up to 8 days after last drug administration
-
Number of subjects with clinically significant findings in laboratory tests
Time frame: up to 8 days after last drug administration
-
Number of subjects with clinically significant findings in vital signs
Time frame: up to 8 days after last drug administration
blood pressure, pulse rate
-
Assessment of global tolerability by investigator on a 5-point scale
Time frame: at the end of each of the visits 2 to 9
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Multiple Dose Seven-way Cross-over Formulation-finding Study Comparing the Oral Bioavailability of Seven Prototype Slow-release Formulations With 0.75 mg Pramipexole (Four Days Each) to Immediate-release Tablets at Steady State in Healthy Male Volunteers
Important dates
- Study start
- 2004
- Primary completion
- 2004
- First posted
- Oct 10, 2014
- Registry last updated
- Oct 10, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details